ArticleMicrobiology spectrum2026
Optimized use of the FilmArray Meningitis/Encephalitis panel for early discontinuation of antibiotic therapy.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Suspected meningitis/encephalitis cases require prompt empirical antimicrobial therapy. Syndromic diagnostics like the FilmArray Meningitis/Encephalitis (FAME) panel offer rapid results and are increasingly used despite high costs. This study assessed FAME's integration in clinical microbiology laboratories' everyday practice and its impact on early treatment decisions. The FilmArray Meningitis/encephalitis panel Outcome Study (FAMOuS) retrospectively reviewed biological data, treatments before/after FAME, and outcomes from 783 patients across six French hospitals over a 3-year period. FAME results were 80% negative, 7% bacterial, and 13% viral, with no bacterial false negatives. Positive results in samples with <10 leukocytes were exclusively seen in immunocompromised individuals and children under 2. Positive results prompted therapeutic changes in 74% of cases, compared to 50% for negatives. FAMOuS enabled the proposal of a decision-support flowchart to optimize the rational use of FAME and support antibiotic stewardship, with the potential to increase early antibiotic discontinuation and reduce unnecessary testing.IMPORTANCEPrompt identification of infectious causes is essential in suspected meningitis and encephalitis, where timely treatment decisions can be lifesaving. The FAMOuS study evaluated the use of the FilmArray Meningitis/Encephalitis (FAME) panel across six French hospitals, analyzing nearly 800 patient episodes. The findings demonstrate that FAME offers reliable results that directly influence clinical management-guiding therapeutic adjustments in most positive cases and supporting early antibiotic discontinuation when appropriate. The study highlights specific patient contexts where FAME provides the greatest clinical value and proposes a decision-support flowchart to optimize its rational use. By integrating rapid molecular diagnostics into everyday practice, this work contributes to improved patient care and reinforces hospital antibiotic stewardship strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.